Paraskevas, Kosmas and Gloviczki, Peter and Antignani, Pier Luigi and Comerota, Anthony J. and Dardik, Alan and Davies, Alun H. and Eckstein, Hans-Henning and Faggioli, Gianluca and Fernandes, Jose Fernandes E. and Fraedrich, Gustav and Geroulakos, George and Golledge, Jonathan and Gupta, Ajay and Gurevich, Victor S. and Jawien, Arkadiusz and Jezovnik, Mateja K. and Kakkos, Stavros K. and Knoflach, Michael and Lanza, Gaetano and Liapis, Christos D. and Loftus, Ian M. and Mansilha, Armando and Nicolaides, Andrew N. and Pini, Rodolfo and Poredos, Pavel and Proczka, Robert M. and Ricco, Jean-Baptiste and Rundek, Tatjana and Saba, Luca and Schlachetzki, Felix and Silvestrini, Mauro and Spinelli, Francesco and Stilo, Francesco and Suri, Jasjit S. and Svetlikov, Alexei and Zeebregts, Clark J. and Chaturvedi, Seemant and Veith, Frank J. and Mikhailidis, Dimitri P. (2022) Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease. PROGRESS IN CARDIOVASCULAR DISEASES, 73. pp. 41-47. ISSN 0033-0620, 1873-1740
Full text not available from this repository. (Request a copy)Abstract
International guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of this multi-disciplinary overview is to summarize the benefits and risks associated with lowering LDL-C with statins or non-statin medications for Asx/SCS patients. The cerebrovascular and CV beneficial effects associated with statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and other non-statin lipid-lowering agents (e.g. fibrates, ezetimibe) are reviewed. The use of statins and PCSK9 inhibitors is associated with several beneficial effects for Asx/SCS patients, including carotid plaque stabilization and reduction of stroke rates. Ezetimibe and fibrates are associated with smaller reductions in stroke rates. The side-effects resulting from statin and PCSK9 inhibitor use are also highlighted. The benefits associated with lowering LDL-C with statins or non-statin lipid lowering agents (e.g. PCSK9 inhibi-tors) outweigh the risks and potential side-effects. Irrespective of their LDL-C levels, all Asx/SCS patients should receive high-dose statin treatment +/- ezetimibe or PCSK9 inhibitors for reduction not only of LDL-C levels, but also of stroke, cardiovascular mortality and coronary event rates.(c) 2022 Elsevier Inc. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | INTIMA-MEDIA THICKNESS; STROKE PREVENTION; DIABETES-MELLITUS; CARDIOVASCULAR EVENTS; AGGRESSIVE REDUCTION; METAANALYSIS; THERAPY; MORTALITY; EFFICACY; SAFETY; Carotid artery stenosis; Best medical treatment; Carotid endarterectomy; Carotid artery stenting; Statins; Proprotein convertase subtilisin; kexin type 9 (PCSK9) inhibitors |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Petra Gürster |
| Date Deposited: | 05 Sep 2023 10:38 |
| Last Modified: | 05 Sep 2023 10:38 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58809 |
Actions (login required)
 |
View Item |
